Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.52 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.52 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19233414 | 0.87 | KDR (0.61) | KDRPDK1CA1CA2CA7 | |
| SCHEMBL23270201 | 0.87 | KDR (0.50) | KDRPDK1LMNAMAPTGAA | |
| SCHEMBL2096593 | 0.87 | KDR (0.71) | KDRPDK1LMNAMAPTGAA | |
| SCHEMBL15600349 | 0.86 | KDR (0.55) | KDRPDK1LMNAMAPTGAA | |
| SCHEMBL24425915 | 0.85 | CA12 (0.47) | KDRPDK1LMNAGAACA1 | |
| SCHEMBL28412734 | 0.85 | PDK1 (0.60) | KDRPDK1LMNAMAPTGAA | |
| SCHEMBL28438966 | 0.84 | PDK1 (0.58) | KDRPDK1LMNAMAPTGAA | |
| SCHEMBL28302624 | 0.84 | PDK1 (0.58) | KDRPDK1LMNAMAPTGAA | |
| SCHEMBL27650492 | 0.84 | AR (0.46) | KDRLMNACA1CA9TMPRSS4 | |
| SCHEMBL31191731 | 0.84 | AR (0.59) | LMNAGRM4CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2019-10-31 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-7425566-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2008-09-16 | — | — | US | disclosed |
| US-7297692-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | disclosed |
| US-20070004703-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-AVENTIS (FR) | 2007-01-04 | — | — | US | disclosed |
| US-7129240-B2 | 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2006-10-31 | — | — | US | disclosed |
| US-7119086-B2 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| CN-1224623-C | 1-phenylsulfonyl-1, 3-dihydro-2H-indol-2-one derivatives, their preparation and their therapeutic use | SANOFI ANWANTE (FR) | 2005-10-26 | — | — | CN | disclosed |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| US-6864277-B2 | 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-08 | — | — | US | disclosed |
| US-20040209938-A1 | Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI (FR) | 2004-10-21 | — | — | US | disclosed |
| CN-1533387-A | 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use | ����ɳŵ��-����������˾ | 2004-09-29 | — | — | CN | disclosed |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| US-6730695-B2 | TREATMENT OF HYPERTENSION, CENTRAL NERVOUS SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-05-04 | — | — | US | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | SANOFI (FR) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | AVPR1B, AVPR1A, AVPR2 | KDR 50/4885PDK1 1742/4885LMNA 2523/4885 |
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | NFATC1, EP300, CD69 | KDR 4808/4885PDK1 1650/4885LMNA 1695/4885 |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | AVPR1B, AVPR1A, AVPR2 | KDR 39/4885PDK1 3080/4885LMNA 2099/4885 |
| US-20040209938-A1 | Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR2, AVPR1B, AVPR1A | KDR 44/4885PDK1 1280/4885LMNA 2501/4885 |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR1B, AVPR2, AVPR1A | KDR 44/4885PDK1 950/4885LMNA 1884/4885 |
| US-20070004703-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVPR1B, AVPR2, AVPR1A | KDR 74/4885PDK1 1101/4885LMNA 2141/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | KDR 1880/4885PDK1 982/4885LMNA 1109/4885 |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | AVPR2, AVPR1A, AVPR1B | KDR 157/4885PDK1 2414/4885LMNA 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.